 |
|
|
| |
Drug-drug interactions (DDIs) in Italian patients with chronic hepatitis C (HCV) treated with pangenotypic direct acting agents (pDAAs): focus on cardiovascular and central nervous system co-medications
|
| |
| |
AASLD 2020 Nov 11-16 virtual
Reported By Jules Levin
(1) Liver Unit, Fondazione "Casa Sollievo Della Sofferenza" Irccs- San Giovanni Rotondo, Italy, (2)Dipartimento Di Oncologia Ed Emato-Oncologia, Universita Degli Studi Di Milano, (3)Hepatology and Liver Transplantation Unit, Azienda Ospedaliero Universitaria, Udine, (4)Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy, (5)Department of Mental Health and Public Medicine - Infectious Diseases Unit, University of Campania Luigi Vanvitelli, (6)Department of Medical Sciences, University of Turin, (7)Clicon S.r.l., Health Economics and Outcomes Research, (8)Gilead Sciences, (9)Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy
|
| |
|
|
|
|
|
